Akari Therapeutics, Plc ( AKTX) - Key Metrics
AKTX Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$2.68 | -$1.74 | -$1.74 |
| 2026Q1 | $0 | -$687.02 | -$118.25 | -$118.25 |
| 2025Q4 | $0 | -$251.81 | -$144.42 | -$144.42 |
| 2025Q3 | $0 | -$391.88 | -$128.69 | -$128.69 |
| 2025Q2 | $0 | -$120.42 | -$206.91 | -$206.91 |
AKTX Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -0.01 |
| 2026Q1 | 0% | 0.00 |
| 2025Q4 | 0% | -0.01 |
| 2025Q3 | 0% | -0.03 |
| 2025Q2 | 0% | -0.10 |
AKTX
Price: $8.62
52 week price:
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United Kingdom
Volume: 16739
Ebitda: -8.5 millionMarket Capitalization: 19.8 million